Quantification of the prentice criteria for surrogate endpoints

被引:11
作者
O'Quigley, J
Flandre, P
机构
[1] INSERM, Inst Curie, F-75005 Paris, France
[2] INSERM, U472, F-94807 Villejuif, France
关键词
explained randomness; information gain; Kaplan-Meier estimator; Kullback-Leibler distance; predictive ability; proportional hazards model; residuals; surrogate endpoint;
D O I
10.1111/j.1541-0420.2006.00538.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In a recent discussion oil the Prentice criteria for surrogate endpoints (1989) and the role of meta. analyses in this context, Alonso et al. (2004, Biometrics 60, 724-728) expand on a number of points. Among these is a suggestion to base a, measure of the degree at which all endpoint meets the Prentice criteria on a likelihood reduction factor. Although new in this context, the suggestion has been studied elsewhere and the measure of Alonso et al., as presented, requires some modification if it is to be useful in general situations. As it stands it depends upon the censoring mechanism, even when independent of the failure mechanism. This is, however, easily Fixed. The measure suggested by Alonso et al. can be seen to fit in with a well-established theory so that, once corrected for the presence of censoring, it can be employed with confidence. Of particular interest is the wide availability of a standard SAS program producing a coefficient which call be immediately transformed to provide all estimate of the population quantity behind the Alonso et al. proposal.
引用
收藏
页码:297 / 300
页数:4
相关论文
共 21 条
  • [1] Allison PD., 2010, SURVIVAL ANAL USING
  • [2] Prentice's approach and the meta-analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints
    Alonso, A
    Molenberghs, G
    Burzykowski, T
    Renard, D
    Geys, H
    Shkedy, Z
    Tibaldi, F
    Abrahantes, JC
    Buyse, M
    [J]. BIOMETRICS, 2004, 60 (03) : 724 - 728
  • [3] Criteria for the validation of surrogate endpoints in randomized experiments
    Buyse, M
    Molenberghs, G
    [J]. BIOMETRICS, 1998, 54 (03) : 1014 - 1029
  • [4] An evaluation of a measure of the proportion of the treatment effect explained by a surrogate marker
    Bycott, PW
    Taylor, JMG
    [J]. CONTROLLED CLINICAL TRIALS, 1998, 19 (06): : 555 - 568
  • [5] COX DR, 1972, J R STAT SOC B, V34, P187
  • [6] DECROIX G, 1984, CANCER, V53, P906, DOI 10.1002/1097-0142(19840215)53:4<906::AID-CNCR2820530415>3.0.CO
  • [7] 2-H
  • [8] A 2-STAGE PROCEDURE FOR SURVIVAL STUDIES WITH SURROGATE END-POINTS
    FLANDRE, P
    OQUIGLEY, J
    [J]. BIOMETRICS, 1995, 51 (03) : 969 - 976
  • [9] Flandre P, 1999, STAT MED, V18, P107, DOI 10.1002/(SICI)1097-0258(19990115)18:1<107::AID-SIM965>3.3.CO
  • [10] 2-G